|
|
 Previous Article | Table of Contents | Next Article 
High levels of interleukin-6 are associated with low tumor burden and low
growth fraction in multiple myeloma
OF Ballester, LC Moscinski, GH Lyman, JV Chaney, HI Saba, AS Spiers and C Klein
Division of Bone Marrow Transplantation, H. Lee Moffitt Cancer Center,
Tampa, FL 33612-9497.
Interleukin-6 (IL-6) is a multifunctional cytokine postulated to play a
central role as a growth factor for multiple myeloma (MM). We evaluated the
spontaneous secretion of IL-6 in supernatants of Ficoll-Hypaque-- enriched
bone marrow (BM) cultures from 35 patients with MM. The levels of IL-6 were
correlated with biological and clinical characteristics of the disease.
High levels of IL-6 production defined a subgroup of patients with low
tumor burden as determined by lower serum beta 2- microglobulin (B2M) (P =
.02) and lower percentage of myeloma cells infiltrating the bone marrow (P
= .003), higher synthetic rates of monoclonal protein (P = .006), and low
proliferative compartments as measured by the percentage of Ki-67--positive
myeloma cells. Patients with high proliferative fractions (Ki-67--positive
myeloma cells > 20%) had significantly lower levels of IL-6 when
compared with patients with low proliferative fractions (P = .005). Our
findings do not support IL- 6 as a major growth factor for MM, but
demonstrate an association of high levels of IL-6 secretion with low tumor
cell burden and low proliferative fraction.
Volume 83,
Issue 7,
pp. 1903-1908,
04/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
298 - 327.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Roodman
Mechanisms of Bone Metastasis
N. Engl. J. Med.,
April 15, 2004;
350(16):
1655 - 1664.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Heider, C. Langelotz, C. Jakob, I. Zavrski, C. Fleissner, J. Eucker, K. Possinger, L. C. Hofbauer, and O. Sezer
Expression of Receptor Activator of Nuclear Factor {kappa}B Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma
Clin. Cancer Res.,
April 1, 2003;
9(4):
1436 - 1440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Roodman
Biology of Osteoclast Activation in Cancer
J. Clin. Oncol.,
August 1, 2001;
19(15):
3562 - 3571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hauser, O. Kajkenova, and D. A. Lipschitz
The Pivotal Role of Interleukin 6 in Formation and Function of Hematopoietically Active Murine Long-Term Bone Marrow Cultures
Stem Cells,
March 1, 1997;
15(2):
125 - 132.
[Abstract]
[Full Text]
|
|
|
|
|
